|
|
|
| home > white papers > Points to Consider When Developing a TMF (Trial Master File) Strategy - Phlexglobal Ltd |
|
|
 WHITE PAPERS |
|
Phlexglobal Ltd
|
|
Points to Consider When Developing a TMF (Trial Master File) Strategy
|
|
Many organizations are currently outsourcing clinical trial activities
to one or more contract research organizations (CROs). This strategy
enables companies to leverage specialized expertise and take advantage
of flexible resourcing throughout the conduct of a clinical trial.
Outsourcing minimizes the costs of recruiting experts, building a team
and maintaining an infrastructure. However, it can also add complexity
as the organization looks to meets its compliance obligations regarding
clinical trial documentation.
The documentation referred to in
Article 15(5) of Directive 2001/20/EC as the trial master file shall
consist of essential documents, which enable both the conduct of a
clinical trial and the quality of the data produced to be evaluated.1
This essential study specific documentation is also known as the TMF. As
organizations try to minimize their reliance on paper files, the
electronic TMF (eTMF) has emerged. A current industry initiative to
standardize the organization of this content is known as the TMF
Reference Model. This model is helping standardization efforts across
paper and electronic systems.
As companies implement outsourcing
strategies, CROs and sponsor organizations look for a common foundation
on which to build their TMF capabilities. The following paper outlines
some of the challenges organizations face when outsourcing clinical
trial activities to multiple contract research organizations and a
strategy to facilitate partnering and management of trial information
between sponsors and CROs.
|
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
International biomed specialist appoints WHP to deliver key expansion project
New state of the art cleanroom facilities will enable a leading
international gene and cell therapy company to expand its bioprocessing
operations and manufacturing capabilities.
More info >> |
|
 |
White Papers |
 |
|
Unmet Medical Needs? Impacted by unmet Life Sciences Staffing Needs?
Clinical Professionals
Whilst the majority of Clinical Professionals clients are working to discover and develop innovative, cost effective medicines that address unmet medical needs they are not impacting the unmet needs of training and developing new recruits into the pharma industry. The impact is highlighted within entry level Clinical Trial Administrators and Clinical Research Associates (CTA/CRA). In the past the Pharmaceutical industry had highly developed training programs for these sought after candidates. As the use of outsourcing models and CRO’s has increased and fewer Pharma businesses embark on their own R&D a substantial gap is developing in newly trained Life Science graduates entering the market to commence a career within R&D. As further financial cuts are made within R&D spend this already dire situation continues to escalate.
More info >> |
|
 |
Industry Events |
 |
ASGCT 22nd Annual Meeting
29 April - 2 May 2019, Washington Hilton, Washington, D.C
The 2019 ASGCT Annual Meeting is expected to be the largest in Society
history, eclipsing the mark set by the 2018 meeting just last year. Join more
than 3,500 researchers, clinicians, advocates, and industry leaders in
discovering the latest science and technology surrounding gene and cell
therapy.
More info >> |
|
|
|
